PMID- 20039942
OWN - NLM
STAT- MEDLINE
DCOM- 20110110
LR  - 20191210
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 17
IP  - 5
DP  - 2010 May
TI  - Different responses to interferon beta-1b treatment in patients with 
      neuromyelitis optica and multiple sclerosis.
PG  - 672-6
LID - 10.1111/j.1468-1331.2009.02897.x [doi]
AB  - BACKGROUND: Although the benefit of treatment for relapsing-remitting multiple 
      sclerosis (MS) is firmly established, whether interferon beta-1b (IFNB-1b) 
      therapy is efficacious for neuromyelitis optica (NMO) has been debated. METHODS: 
      We reviewed the responses to IFNB-1b treatment in 18 patients with relapsing NMO 
      and compared the results with those from 38 patients with relapsing-remitting MS. 
      We compared clinical characteristics, the annualized relapse rate (ARR) and the 
      probability of being relapse free before and after IFNB-1b treatment in patients 
      with NMO and MS. RESULTS: The proportion of patients with more than 50% increase 
      in the ARR after IFNB-1b treatment was much higher in NMO than in MS (P = 0.046). 
      ARR was significantly lower in patients with MS after IFNB-1b administration than 
      before (P = 0.015), but not in NMO. Kaplan-Meier and log-rank statistical 
      analyses revealed that relapse-free rates were lower in NMO than MS after IFNB-1b 
      treatment (P = 0.032). The analyses also showed lower relapse-free rates during 
      the pre-IFNB-1b treatment period than the post-IFNB-1b treatment period in MS (P 
      < 0.001), but not in NMO. CONCLUSION: IFNB-1b treatment does not appear to be 
      effective for preventing relapse in NMO likely because of differences between the 
      immune-pathogenesis of NMO and MS.
FAU - Uzawa, A
AU  - Uzawa A
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, 
      Japan. a-uzimp1204@graduate.chiba-u.jp
FAU - Mori, M
AU  - Mori M
FAU - Hayakawa, S
AU  - Hayakawa S
FAU - Masuda, S
AU  - Masuda S
FAU - Kuwabara, S
AU  - Kuwabara S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20091221
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Adjuvants, Immunologic)
RN  - 145155-23-3 (Interferon beta-1b)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/adverse effects
MH  - Adult
MH  - Female
MH  - Humans
MH  - Immunity, Cellular
MH  - Interferon beta-1b
MH  - Interferon-beta/*administration & dosage/adverse effects
MH  - Lymphocytes/immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*drug therapy/immunology
MH  - Multiple Sclerosis, Relapsing-Remitting/drug therapy/immunology
MH  - Neuromyelitis Optica/*drug therapy/immunology
MH  - Outcome Assessment, Health Care/methods
MH  - Recurrence
MH  - Retrospective Studies
MH  - Treatment Failure
MH  - Treatment Outcome
EDAT- 2009/12/31 06:00
MHDA- 2011/01/11 06:00
CRDT- 2009/12/31 06:00
PHST- 2009/12/31 06:00 [entrez]
PHST- 2009/12/31 06:00 [pubmed]
PHST- 2011/01/11 06:00 [medline]
AID - ENE2897 [pii]
AID - 10.1111/j.1468-1331.2009.02897.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2010 May;17(5):672-6. doi: 10.1111/j.1468-1331.2009.02897.x. Epub 
      2009 Dec 21.